Show simple item record

dc.contributor.authorGirardi, F
dc.contributor.authorBarnes, DR
dc.contributor.authorBarrowdale, D
dc.contributor.authorFrost, D
dc.contributor.authorBrady, AF
dc.contributor.authorMiller, C
dc.contributor.authorHenderson, A
dc.contributor.authorDonaldson, A
dc.contributor.authorMurray, A
dc.contributor.authorBrewer, C
dc.contributor.authorPottinger, C
dc.contributor.authorEvans, DG
dc.contributor.authorEccles, D
dc.contributor.authorEMBRACE,
dc.contributor.authorLalloo, F
dc.contributor.authorGregory, H
dc.contributor.authorCook, J
dc.contributor.authorEason, J
dc.contributor.authorAdlard, J
dc.contributor.authorBarwell, J
dc.contributor.authorOng, KR
dc.contributor.authorWalker, L
dc.contributor.authorIzatt, L
dc.contributor.authorSide, LE
dc.contributor.authorKennedy, MJ
dc.contributor.authorTischkowitz, M
dc.contributor.authorRogers, MT
dc.contributor.authorPorteous, ME
dc.contributor.authorMorrison, PJ
dc.contributor.authorEeles, R
dc.contributor.authorDavidson, R
dc.contributor.authorSnape, K
dc.contributor.authorEaston, DF
dc.contributor.authorAntoniou, AC
dc.date.accessioned2018-04-11T09:21:57Z
dc.date.issued2018-12-01
dc.identifier.citationGenetics in medicine : official journal of the American College of Medical Genetics, 2018, 20 (12), pp. 1575 - 1582
dc.identifier.issn1098-3600
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/1637
dc.identifier.eissn1530-0366
dc.identifier.doi10.1038/gim.2018.44
dc.description.abstractPURPOSE: BRCA1/BRCA2 predictive test negatives are proven noncarriers of a BRCA1/BRCA2 mutation that is carried by their relatives. The risk of developing breast cancer (BC) or epithelial ovarian cancer (EOC) in these women is uncertain. The study aimed to estimate risks of invasive BC and EOC in a large cohort of BRCA1/BRCA2 predictive test negatives. METHODS: We used cohort analysis to estimate incidences, cumulative risks, and standardized incidence ratios (SIRs). RESULTS: A total of 1,895 unaffected women were eligible for inclusion in the BC risk analysis and 1,736 in the EOC risk analysis. There were 23 incident invasive BCs and 2 EOCs. The cumulative risk of invasive BC was 9.4% (95% confidence interval (CI) 5.9-15%) by age 85 years and the corresponding risk of EOC was 0.6% (95% CI 0.2-2.6%). The SIR for invasive BC was 0.93 (95% CI 0.62-1.40) in the overall cohort, 0.85 (95% CI 0.48-1.50) in noncarriers from BRCA1 families, and 1.03 (95% CI 0.57-1.87) in noncarriers from BRCA2 families. The SIR for EOC was 0.79 (95% CI 0.20-3.17) in the overall cohort. CONCLUSION: Our results did not provide evidence for elevated risks of invasive BC or EOC in BRCA1/BRCA2 predictive test negatives.
dc.formatPrint-Electronic
dc.format.extent1575 - 1582
dc.languageeng
dc.language.isoeng
dc.publisherNATURE PUBLISHING GROUP
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.subjectEMBRACE
dc.subjectHumans
dc.subjectBreast Neoplasms
dc.subjectOvarian Neoplasms
dc.subjectGenetic Predisposition to Disease
dc.subjectBRCA1 Protein
dc.subjectBRCA2 Protein
dc.subjectRisk Assessment
dc.subjectRisk Factors
dc.subjectGerm-Line Mutation
dc.subjectAdult
dc.subjectAged
dc.subjectMiddle Aged
dc.subjectFemale
dc.titleRisks of breast or ovarian cancer in BRCA1 or BRCA2 predictive test negatives: findings from the EMBRACE study.
dc.typeJournal Article
dcterms.dateAccepted2018-01-12
rioxxterms.versionofrecord10.1038/gim.2018.44
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by-nc-sa/4.0
rioxxterms.licenseref.startdate2018-12
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfGenetics in medicine : official journal of the American College of Medical Genetics
pubs.issue12
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Genetics and Epidemiology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Genetics and Epidemiology/Oncogenetics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Oncogenetics
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Genetics and Epidemiology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Genetics and Epidemiology/Oncogenetics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Oncogenetics
pubs.publication-statusPublished
pubs.volume20
pubs.embargo.termsNot known
icr.researchteamOncogenetics
dc.contributor.icrauthorEeles, Rosalind


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0